NLK and neuroblastoma: In neuroblastoma, miR-221 enhances mycn protooncogene, bhlh transcription factor (MYCN) oncoprotein levels by targeting Nemo-like kinase (NLK), a negative regulator of MYCN; high miR-221 expression correlates with advanced disease and poor prognosis [32].